Business
New data for SCIB1 in metastatic melanoma
New data for SCIB1 in metastatic melanoma.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 9752U Scancell Holdings Plc 09 December 2013 \n \n\n9 December 2013\n \n \nScancell Holdings Plc\n \nCompelling new immune response data and promising survival trend suggest potential for SCIB1 as an effective novel therapy in metastatic melanoma\n \nScancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce encouraging results from Part 2 of its on-going Phase 1/2 clinical trial in patients with Stage III/IV melanoma treated with the SCIB1 ImmunoBodyÒ as well as an update from patients in Part 1 of the study. \n \nHighlights\n \nPart 2 study results\n· All 14 study patients produced a melanoma-specific T-cell response to treatment\n· All patients are still alive; only three patients have any evidence of disease progression\n· Median survival time of Part 2 patients since initiating treatment is currently 15 months; 21 months since diagnosis of metastatic disease \n· Six patients are continuing on extended, long-term treatment with SCIB1\n· SCIB1 therapy was well tolerated with no reports of serious drug-related side effects in line with results reported from Part 1 of the study\n \nPart 1 study update\n· The four patients who were alive at the time of the initial Part 1 report (December 2012) remain alive\n· Median survival time in Part 1 patients who received at least three treatments with the 2mg/4mg doses of SCIB1 is now 25 months\n \nThese results confirm that Scancell's SCIB1 ImmunoBodyÒ therapy is producing a melanoma-specific immune response in patients with Stage III/IV melanoma. This is particularly evident in patients with resected disease. Together with the immunological and clinical data from Part 1 of the study, the results suggest that these induced immune responses might also be contributing to the control of tumour in these patients.\n \nProf Lindy Durrant, Joint CEO of Scancell Holdings and Professor of Cancer Immunotherapy at Nottingham University, commented: \"These results exceeded our highest expectations confirming that SCIB1 induces a consist...